Publications by authors named "Afaf Raibouaa"
Objectives: We aimed to quantify patient preferences for efficacy, safety and convenience features of atopic dermatitis (AD) treatments.
Design And Setting: Online discrete choice experiment survey.
Participants: Adults in the UK, France and Spain who had used AD treatments during the past 2 years.
Article Synopsis
- The study used indirect treatment comparison to evaluate the effectiveness of baricitinib vs. dupilumab in adult patients with moderate-to-severe atopic dermatitis, focusing on approved doses.
- At weeks 4 and 16, baricitinib showed a greater improvement in itch scores than dupilumab, particularly in patients using it as monotherapy or alongside topical corticosteroids, though differences weren't as pronounced at week 16.
- Overall, baricitinib may provide faster relief from itching while maintaining similar levels of overall skin improvement and quality of life compared to dupilumab.